How We Mark Time and How Time Marks Us
Dr. Gotlib discusses the road to approval of midostaurin for the treatment of advanced systemic mastocytosis.
A Randomized Trial in a Rare Cancer: Targeting CD30 in Cutaneous T Cell Lymphoma Yields Therapeutic Dividends
Dr. Roberts discusses a trial that looks at new therapies to be tested for the treatment of a rare cancer, cutaneous T cell lymphoma.
Dr. Garcia takes a look at the best of 2016 in the field of platelet disorders and within nonmalignant hematology through a randomized trial that compared standard care to standard care plus platelet transfusion in adult patients who were taking antiplatelet drugs and experienced ICH.
Dr. Garcia discusses a study that tests a new therapeutic approach with antifibrinolytic agents to chemotherapy-associated thrombocytopenia.
Dr. Garcia covers a study that suggests that emicizumab, a bispecific antibody, may allow many patients with Hemophilia A to achieve better hemostasis and might even be a better option than currently available treatments with inhibitors.
Dr. Garcia highlights clinical recommendations from the ACCP's evidence-based guidelines for the treatment of venous thromboembolism (VTE) that are most relevant to hematologists.
Dr. Garcia discusses two approaches to the use of corticosteroids for the treatment of immune thrombocytopenia.
Dr. Garcia takes a look at a study that observes treatment of cancer patients after a breakthrough VTE to help clinicians and investigators define management of patients experiencing VTE recurrence despite anticoagulation.
Dr. Garcia discusses trials in the past year that invalidated two myths regarding nonmalignant hematology.
Dr. Garcia reviews a study that shows the importance of an accurate 4Ts assessment.
Dr. Garcia discusses a study that will examine whether edoxaban, an oral FXa inhibitor, is as effective as LMWH in patients with cancer-associated thrombosis.
Dr. Garcia discusses treatment with direct oral anticoagulants (DOACs), after the FDA approval of edoxaban, the fourth DOAC to come to the U.S. market since 2010.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology